June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Advantages of tafluprost/timolol fixed-dose combination in the view points of efficacy duration and corneal safety
Author Affiliations & Notes
  • Takahiro Akaishi
    Research & Development Division Santen Pharmaceutical Co., Ltd., Ikoma, Japan
  • Tomoko Kirihara
    Research & Development Division Santen Pharmaceutical Co., Ltd., Ikoma, Japan
  • Naoko Yamashita
    Research & Development Division Santen Pharmaceutical Co., Ltd., Ikoma, Japan
  • Kenji Ueda
    Research & Development Division Santen Pharmaceutical Co., Ltd., Ikoma, Japan
  • Atsushi Shimazaki
    Research & Development Division Santen Pharmaceutical Co., Ltd., Ikoma, Japan
  • Hidetoshi Mano
    Research & Development Division Santen Pharmaceutical Co., Ltd., Ikoma, Japan
  • Kouichi Kawazu
    Research & Development Division Santen Pharmaceutical Co., Ltd., Ikoma, Japan
  • Footnotes
    Commercial Relationships Takahiro Akaishi, Santen Pharmaceutical Co. Ltd. (E); Tomoko Kirihara, Santen Pharmaceutical Co. Ltd. (E); Naoko Yamashita, Santen Pharmaceutical Co. Ltd. (E); Kenji Ueda, Santen Pharmaceutical Co. Ltd. (E); Atsushi Shimazaki, Santen Pharmaceutical Co. Ltd. (E); Hidetoshi Mano, Santen Pharmaceutical Co. Ltd. (E); Kouichi Kawazu, Santen Pharmaceutical Co. Ltd. (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5697. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Takahiro Akaishi, Tomoko Kirihara, Naoko Yamashita, Kenji Ueda, Atsushi Shimazaki, Hidetoshi Mano, Kouichi Kawazu; Advantages of tafluprost/timolol fixed-dose combination in the view points of efficacy duration and corneal safety. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5697.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: TAPCOM, 0.0015% tafluprost/0.5% timolol fixed-dose combination (Taf/T FDC) with preservative, is a new prostaglandin analog (PGA) and β-adrenergic antagonist (β-blocker) FDC. In this study, we compared the duration of ocular hypotensive efficacy, timolol penetration into the aqueous humor (AH), and in vitro corneal cytotoxicity of Taf/T FDC with other PGA + β-blocker FDCs.

Methods: Ocular hypotensive efficacy was assessed by measuring the intraocular pressure (IOP) using a pneumatonometer in ocular normotensive cynomolgus monkeys. IOP was measured before and 4-8, 12-18, and 24-30 h after a single instillation of Taf/T FDC, 0.005% latanoprost/0.5% timolol FDC (Lat/T FDC; Xalacom®), or saline. Timolol penetration into the AH was measured using LC-MS after a single instillation of Taf/T FDC or Lat/T FDC to SD rats. In vitro corneal cytotoxicity was evaluated using an MTS assay in SV40-immortalized human corneal epithelial cells (HCE-T). Cytotoxicities of PGA + β-blocker FDCs and 10-fold diluted PGA + β-blocker FDCs were evaluated within 5 min of exposure and 5 to 30 min after exposure, respectively.

Results: The ocular hypotensive efficacy of Taf/T FDC was equivalent to that of Lat/T FDC at 4-12 h, with the peak IOP exhibited at 8 h and measured values being 4.4 ± 0.2 mmHg (p < 0.01 vs. saline) and 4.5 ± 0.4 mmHg (p < 0.01 vs. saline), respectively. However, Taf/T FDC showed significantly greater IOP reduction than Lat/T FDC at 24-30 h, with the efficacy of Taf/T FDC sustained for more than 30 h. The AH concentration of timolol in the Taf/T FDC-administered eye was higher than that in the Lat/T FDC-administered eye (3870 ng/mL vs. 1330 ng/mL in Cmax). In the MTS assay, reduction of cell viability by 5-min exposure to Taf/T FDC, BAK free 0.004% travoprost/0.5% timolol FDC (Tra/T FDC; DuoTrav®), and Lat/T FDC was 15.8%, 13.9%, and 95.7%, respectively, and that by 30-min exposure to 10-fold diluted Taf/T FDC, Tra/T FDC, and Lat/T FDC was 11.5%, 13.7%, and 70.6%, respectively.

Conclusions: The ocular hypotensive efficacy of Taf/T FDC sustained longer than that of Lat/T FDC. In addition, corneal cytotoxicity of Taf/T FDC was comparable to that of BAK-free Tra/T FDC and was significantly weaker than that of Lat/T FDC. Thus, these results suggest that Taf/T FDC is a better product with respect to efficacy duration and corneal safety compared with Lat/T FDC.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×